Diagnostic significance of serum cystatin C and complement component C1q antibody in lupus nephritis
- VernacularTitle:Люпус нефритийн оношилгоонд ийлдэсний цистатин С болон хавсарга С1q уургийн эсрэг бие тодорхойлж ач холбогдлыг судалсан үр дүн
- Author:
Tsedensodnom B
1
,
2
;
Altanzul B
1
;
Baigalmaa E
3
;
Zulgerel D
1
Author Information
1. Department of Rheumatology, School of Medicine, MNUMS
2. Outpatient Department, Bayangol District Health Center
3. Internal Department II, Intermed Hospital
- Publication Type:Journal Article
- Keywords:
Lupus nephritis;
Biomarker;
Cystatin C;
Anti-C1q;
eGFR
- From:
Mongolian Journal of Health Sciences
2025;85(1):62-66
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Systemic lupus erythematosus (SLE) is an unknown systemic autoimmune disease that causes multiple
tissue and organ damage. Lupus nephritis (LN) was found to occur in 15-30% of the patients with lupus at the time of
initial diagnosis and in 30-50% during disease progression. Accurate diagnosis and active treatment can preserve the
kidney function of LN patients and delay the process of kidney fibrosis, thus postponing the occurrence and development
of end-stage kidney disease (ESRD). The diagnosis of LN is ideally confirmed by histologic findings in a kidney biopsy.
Additionally, serum or urine biomarkers such as serum creatinine, urea, and immune-related molecules, such as anti-double-stranded DNA, anticardiolipin, complement components C3, C4, and anti-C1q antibodies.
Aim:The information concerning non-invasive, easy, and accurate biomarkers for diagnosis of lupus nephritis. This study
aimed to evaluate the diagnostic significance of cystatin C and complement component 1q antibody for lupus nephritis.
Materials and Methods:A study that included 40 patients with systemic lupus erythematosus (SLE) without LN
(non-Lupus group), 40 patients with lupus nephritis (Lupus group) was performed in a hospital based cross-sectional
study from May 2022 to August 2024. The serum levels of CysC, Anti-C1q, urea, and creatinine were measured, and
estimated glomerular filtration rates (eGFRCysC
, eGFRcreat
, eGFRcomb) were calculated by equations two groups and the
CKD-EPI respectively. T-test analysis or Chi-square test was used to compare the differences between the two groups.
The receiver operating characteristic (ROC) curve was applied to identify the diagnostic efficiencies of individual or
combined multiple indicators.
Results:80 patients were recruited, including 5% men and 95% women with a mean age of 35.15±9.57 years (range 17-56 years). The LN group with a mean age of 35.2±9.44 years, non-LN group with a mean age of 35.1 ±9.38 years. The
non-LN group clinical manifestation of 47.5% arthritis, 32.5% hematologic system, 10% interstitial lung disease, 7.5%
dermatitis, 2.5% central nervous system. The LN group with SLE disease activity index of 85% severe activity, 2.5%
moderate activity, 2.5% mild activity. The non-LN group with SLE disease activity index of 7.5% severe activity, 62.5%
moderate activity, 20% mild activity, 10% low activity. Significantly elevated Cystatin C and anti-C1q were observed in
the LN groups. Cystatin C, creatinine, urea and antiC1q were increased 60% (n=24), 22.5% (n=9), 32.5% (n=13), and
70% (n=28) respectively (P=0.001). eGFRcreat
detected chronic kidney disease (CKD) stage of 63.7% normal, 25% mild,
and 11.25% moderate stage. eGFRcyst
detected chronic kidney disease (CKD) stage of 47.5% normal, 25% mild, 20%
moderate, 7.5% severe stage.
Conclusion: The separately detected cystatin C(eGFRcyst) and antiC1q were superior to the conventional biomarkers
Urea, Creat, and eGFRcreat
in the diagnosis of lupus nephritis with SLE.
- Full text:202505271418573078362-66.pdf
